Growth inhibition by NVP-BEZ235, a dual PI3K/mTOR inhibitor, in hepatocellular carcinoma cell lines

Oncology Reports

Volumn 26, Issue 5, 2011, Pages 1273-1279

  Masuda, Mitsuhiro ^a,b   Shimomura, Manami ^a   Kobayashi, Ken ^c   Kojima, Shuji ^b   Nakatsura, Tetsuya ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b TOKYO UNIVERSITY OF SCIENCE   (Japan)

^c NOVARTIS PHARMA K K   (Japan)

Author keywords

Akt; Hepatocellular carcinoma; NVP BEZ235; PI3 kinase; Rapamycin

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P110; PROTEIN P110 ALPHA; S6 KINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL GROWTH PROCESSES; CELL LINE, TUMOR; FEMALE; HUMANS; IMIDAZOLES; LIVER NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; PHOSPHATIDYLINOSITOL 3-KINASE; QUINOLINES; TOR SERINE-THREONINE KINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80053134885     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1370     Document Type: Article

References (25)

1. El-Serag HB and Rudolph KL: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132: 2557-2576, 2007. (Pubitemid 46890874)
2. Sherman M: Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis. Semin Liver Dis 30: 3-16, 2010.
3. Cantley LC: The phosphoinositide 3-kinase pathway. Science 296: 1655-1657, 2002.
4. Vivanco I and Sawyers CL: The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489-501, 2002. (Pubitemid 37328931)
5. Alessi DR, James SR, Downes CP, et al: Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol 7: 261-269, 1997. (Pubitemid 27176852)
6. Sarbassov DD, Ali SM, Sengupta S, et al: Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 22: 159-168, 2006.
7. Manning BD and Cantley LC: AKT/PKB signaling: navigating downstream. Cell 129: 1261-1274, 2007. (Pubitemid 46962095)
8. Foster KG and Fingar DC: Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony. J Biol Chem 285: 14071-14077, 2010.
9. Sansal I and Sellers WR: The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 22: 2954-2963, 2004. (Pubitemid 41079915)
10. Phillips WA, St Clair F, Munday AD, Thomas RJ and Mitchell CA: Increased levels of phosphatidylinositol 3-kinase activity in colorectal tumors. Cancer 83: 41-47, 1998. (Pubitemid 28299627)
11. Benistant C, Chapuis H and Roche S: A specific function for phosphatidylinositol 3-kinase alpha (p85alpha-p110alpha) in cell survival and for phosphatidylinositol 3-kinase beta (p85alpha-p110beta) in de novo DNA synthesis of human colon carcinoma cells. Oncogene 19: 5083-5090, 2000.
12. Yuan ZQ, Sun M, Feldman RI, et al: Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. Oncogene 19: 2324-2330, 2000. (Pubitemid 30307208)
13. Cantley LC and Neel BG: New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 96: 4240-4245, 1999. (Pubitemid 29190320)
14. Samuels Y, Wang Z, Bardelli A, et al: High frequency of mutations of the PIK3CA gene in human cancers. Science 304: 554, 2004. (Pubitemid 38541907)
15. Shayesteh L, Lu Y, Kuo WL, et al: PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 21: 99-102, 1999. (Pubitemid 29036292)
16. Lee JW, Soung YH, Kim SY, et al: PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 24: 1477-1480, 2005. (Pubitemid 40343128)
17. Hu TH, Huang CC, Lin PR, et al: Expression and prognostic role of tumor suppressor gene PTEN/MMAC1/TEP1 in hepatocellular carcinoma. Cancer 97: 1929-1940, 2003.
18. Zhou L, Huang Y, Li J and Wang Z: The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma. Med Oncol 27: 255-261, 2010.
19. Maira SM, Stauffer F, Brueggen J, et al: Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 7: 1851-1863, 2008.
20. Baumann P, Mandl-Weber S, Oduncu F and Schmidmaier R: The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma. Exp Cell Res 315: 485-497, 2009.
21. Cao P, Maira SM, Garcia-Echeverria C and Hedley DW: Activity of a novel, dual PI3-kinase/mTOR inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts. Br J Cancer 100: 1267-1276, 2009.
22. Marone R, Erhart D, Mertz AC, et al: Targeting melanoma with dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors. Mol Cancer Res 7: 601-613, 2009.
23. Fujise K, Nagamori S, Hasumura S, et al: Integration of hepatitis B virus DNA into cells of six established human hepatocellular carcinoma cell lines. Hepatogastroenterology 37: 457-460, 1990.
24. Beerheide W, Tan YJ, Teng E, Ting AE, Jedpiyawongse A and Srivatanakul P: Down-regulation of proapoptotic proteins Bax and Bcl-X(S) in p53 overexpressing hepatocellular carcinomas. Biochem Biophys Res Commun 273: 54-61, 2000. (Pubitemid 30426862)
25. Takehara T, Liu X, Fujimoto J, Friedman SL and Takahashi H: Expression and role of Bcl-xL in human hepatocellular carcinomas. Hepatology 34: 55-61, 2001. (Pubitemid 32591483)